Latest Insider Transactions at Collegium Pharmaceutical, Inc (COLL)
This section provides a real-time view of insider transactions for Collegium Pharmaceutical, Inc (COLL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of COLLEGIUM PHARMACEUTICAL, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of COLLEGIUM PHARMACEUTICAL, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,600
-7.53%
|
$844,800
$48.28 P/Share
|
|
Dec 08
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,600
+12.68%
|
$264,000
$15.9 P/Share
|
|
Dec 05
2025
|
Rita J. Balice Gordon |
SELL
Open market or private sale
|
Direct |
3,650
-6.49%
|
$171,550
$47.03 P/Share
|
|
Nov 12
2025
|
Vikram Karnani President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,983
-8.48%
|
$422,201
$47.35 P/Share
|
|
Nov 12
2025
|
John A. Fallon |
SELL
Open market or private sale
|
Direct |
34,853
-35.03%
|
$1,638,091
$47.21 P/Share
|
|
Nov 12
2025
|
John A. Fallon |
BUY
Exercise of conversion of derivative security
|
Direct |
34,853
+16.24%
|
$418,236
$12.91 P/Share
|
|
Nov 06
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-9.87%
|
$1,200,000
$40.83 P/Share
|
|
Aug 29
2025
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,478
-19.92%
|
$664,164
$38.42 P/Share
|
|
Aug 18
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
16,389
-13.66%
|
$622,782
$38.21 P/Share
|
|
Aug 18
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,389
+12.02%
|
$344,169
$21.34 P/Share
|
|
Aug 15
2025
|
Gino Santini Director |
SELL
Open market or private sale
|
Direct |
5,405
-5.38%
|
$199,985
$37.19 P/Share
|
|
Aug 15
2025
|
Gino Santini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.99%
|
$195,000
$13.45 P/Share
|
|
Aug 13
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,861
-4.48%
|
$184,718
$38.03 P/Share
|
|
Aug 13
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,861
+4.29%
|
$102,081
$21.34 P/Share
|
|
Aug 13
2025
|
Rubric Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,000
-0.79%
|
$925,000
$37.85 P/Share
|
|
Aug 08
2025
|
John Gordon Freund Director |
SELL
Open market or private sale
|
Indirect |
11,659
-33.51%
|
$396,406
$34.36 P/Share
|
|
Jun 09
2025
|
John Gordon Freund Director |
SELL
Open market or private sale
|
Direct |
6,601
-8.54%
|
$198,030
$30.62 P/Share
|
|
Jun 09
2025
|
John Gordon Freund Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+16.26%
|
$195,000
$13.45 P/Share
|
|
May 15
2025
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+13.59%
|
-
|
|
May 15
2025
|
Rita J. Balice Gordon |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+14.82%
|
-
|
|
May 15
2025
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+13.59%
|
-
|
|
May 15
2025
|
Nancy Lurker Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+30.31%
|
-
|
|
May 15
2025
|
John A. Fallon |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+13.16%
|
-
|
|
May 15
2025
|
Carlos V Paya Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,582
+50.0%
|
-
|
|
May 15
2025
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+10.28%
|
-
|
|
Mar 21
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,881
-15.41%
|
$566,430
$30.03 P/Share
|
|
Mar 21
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,396
-3.92%
|
$191,880
$30.03 P/Share
|
|
Mar 20
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,927
-1.55%
|
$57,810
$30.0 P/Share
|
|
Mar 20
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,206
-0.73%
|
$36,180
$30.0 P/Share
|
|
Mar 17
2025
|
David Dieter EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
68,449
+50.0%
|
-
|
|
Mar 14
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
977
-0.59%
|
$29,310
$30.0 P/Share
|
|
Mar 14
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,255
-1.78%
|
$67,650
$30.0 P/Share
|
|
Mar 11
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,445
-5.95%
|
$313,350
$30.01 P/Share
|
|
Mar 07
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,348
-1.63%
|
$70,440
$30.0 P/Share
|
|
Mar 07
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,504
-0.85%
|
$45,120
$30.0 P/Share
|
|
Mar 06
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,682
-6.53%
|
$560,460
$30.0 P/Share
|
|
Mar 06
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,949
-1.09%
|
$58,470
$30.0 P/Share
|
|
Mar 06
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
26,067
-19.42%
|
$729,876
$28.5 P/Share
|
|
Mar 05
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
20,000
-12.97%
|
$560,000
$28.03 P/Share
|
|
Mar 04
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
40,000
-20.6%
|
$1,120,000
$28.08 P/Share
|
|
Mar 04
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+17.08%
|
$960,000
$24.03 P/Share
|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
30,426
-7.47%
|
$912,780
$30.52 P/Share
|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,725
+16.74%
|
-
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,623
-8.64%
|
$888,690
$30.52 P/Share
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,427
+17.97%
|
-
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,897
-3.19%
|
$176,910
$30.52 P/Share
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,075
+16.51%
|
-
|
|
Feb 10
2025
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,820
+8.74%
|
-
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
34,975
-9.61%
|
$1,049,250
$30.52 P/Share
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
69,995
+16.84%
|
-
|